The popularity of Viagra initially fueled a surge for major pharmaceutical companies, however recent shifts present a complicated picture for shareholders. Off-patent competitors are reducing profits, and continued legal battles add more complexity to the equation. While specific companies might still benefit from complementary products, the broade